Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross‐sectional survey

Wolf, Peter; Weger, Wolfgang; Legat, Franz J.; Painsi, Clemens; Saxinger, Werner; Müllegger, Robert R.; Sator, Paul; Ratzinger, Gudrun; Selhofer, Sylvia; Richter, Leo; Salmhofer, Wolfgang; Lange‐Asschenfeldt, Bernhard; Trautinger, Franz; Mlynek, Alexander; Strohal, Robert; Augustin, Matthias; Quehenberger, Franz

doi:10.1111/ddg.13613

Cited by 9 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is supported by data from Austria. In a comparable cross‐sectional study, the proportion of psoriasis patients with DLQI > 10 was equally high 18 . Thus, no further improvement in the quality of care can be assumed in this indicator.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017

Langenbruch

Mohr

Kirsten

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background In the study series PsoHealth first data from 2004/05 showed a poor quality of health care for psoriasis in Germany. Most patients lacked sufficient care and only a minor proportion received systemic drugs. Since 2007, a national psoriasis programme has been conducted. Objectives (1) To analyse the quality of health care for psoriasis in the most recent PsoHealth4 survey 2016/17, (2) to compare health care quality indicators with prior assessments since 2004/05. Materials and methods The recent cross‐sectional PsoHealth4 survey was conducted 2016/17, and three preceding studies were performed in 2004/05, 2007 and 2013/14, each including at least 1500 patients. The common set of quality indicators included disease severity (PASI and proportion of patients with PASI > 20, indicating high severity), quality of life (DLQI and proportion of patients with DLQI > 10, indicating strong impairments in quality of life), systemic therapy and inpatient treatment of the last five years. Results Between December 2015 and December 2017, n = 1827 patients from 93 dermatological centres were included in the most recent survey (mean age: 50.8 ± 14.6 years, 45.2% female). 7.3% showed a PASI > 20, compared to 17.8% in 2004/05. 21.4% reported a DLQI > 10, compared to 34.0% in 2004/05. 57.6% of all participants stated to have received a systemic therapy at least once within the last five years, compared to 32.9% in 2004/05. 18.0% received inpatient hospital treatment at least once within the last five years, compared to 26.9% in 2004/05. Conclusion A remarkable improvement in the health care quality for psoriasis patients in Germany within the past 12 years can be assumed. Major determinants could be the innovation shift which included programmes such as the S3 guideline, a consensus on treatment goals, national health care goals for psoriasis and higher utilisation of innovative drugs.

show abstract

Section: Discussionmentioning

confidence: 91%

“…In a comparable cross-sectional study, the proportion of psoriasis patients with DLQI > 10 was equally high. 18 Thus, no further improvement in the quality of care can be assumed in this indicator. This could be explained by a high level in quality of PSO care that has already been achieved.…”

Section: Discussionmentioning

confidence: 99%

Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017

Langenbruch

Mohr

Kirsten

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Patients with longer disease duration at baseline treated with guselkumab also responded significantly better than those treated with secukinumab. In real-world practice, despite the variety of treatment options for psoriasis, some patients continue to experience psoriasis activity (27). When considering available treatment options, it is useful for clinicians to have comparative data, like those presented here, when making treatment decisions for patients of varying demographics and disease characteristics.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

Blauvelt

Armstrong

Langley

et al. 2021

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Purpose: Guselkumab, an interleukin (IL)-23 inhibitor, effectively treats moderate-to-severe plaque psoriasis. Materials and methods: ECLIPSE, was a Phase 3, multicenter, 56-week, double-blinded, active-comparator study of guselkumab vs. secukinumab (IL-17A inhibitor) in patients with moderate-to-severe psoriasis. Patients were treated with guselkumab 100 mg (n ¼ 534) or secukinumab 300 mg (n ¼ 514) through week 44. Efficacy (at least a 90% and 100% improvement from baseline in Psoriasis Area and Severity Index [PASI 90 and PASI 100], Investigator's Global Assessment [IGA] 0/1, and IGA 0) was analyzed across subpopulations defined by baseline: age (<45, 45 to <65, and !65 years old), body weight, body mass index (BMI), psoriasis disease severity (body surface area, disease duration, PASI, and IGA), psoriasis by body regions (head, trunk, upper and lower extremities), and prior psoriasis medication history at week 48. Results: Overall, 1048 patients were randomized. At week 48, numerically greater proportions of patients achieved PASI 90, PASI 100, IGA 0/1, and IGA 0 with guselkumab vs. secukinumab regardless of baseline age, body weight, BMI, disease severity, body region, and prior medication. The largest differences were in patients !65 years old and patients weighing >100 kg. Conclusions: Guselkumab treatment provided greater efficacy vs. secukinumab at week 48 in most subpopulations of patients with psoriasis.

show abstract

“…conducted a quality of life study among Austrian patients with psoriasis: there were 1184 participants, of whom 42.1% reported that at least 11.2% of body surface area was affected. The authors observed that 97.2% had used topical therapies since disease onset, but over the final 4 weeks of the study, only 88.2% were still using topical agents . Overall, the data from these three distinct studies suggests that adherence to topical therapies is complex, and is influenced by several factors.…”

mentioning

confidence: 99%

“…Finally, Wolf et al . conducted a quality of life study among Austrian patients with psoriasis: there were 1184 participants, of whom 42.1% reported that at least 11.2% of body surface area was affected.…”

mentioning

confidence: 99%

What lessons can we learn from an apparent decrease in the use of topical drugs for psoriasis?

Criado

2019

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross‐sectional survey

Abstract: Despite dermatological care, the majority of Austrian psoriasis patients continues to experience impaired quality of life; there is potential for improvement in the achievement of treatment goals.

Cited by 9 publications

References 23 publications

Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017

Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004‐2017

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

What lessons can we learn from an apparent decrease in the use of topical drugs for psoriasis?

Contact Info

Product

Resources

About